Coherus Oncology (CHRS) Total Non-Current Liabilities (2013 - 2026)

Coherus Oncology has disclosed Total Non-Current Liabilities across 14 years of filings, most recently posting $185.9 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $185.9 million, down 66.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $185.9 million (down 66.44% YoY), and the FY2025 annual result was $178.9 million, down 67.54% from the prior year.
• Total Non-Current Liabilities came in at $185.9 million for Q1 2026 at Coherus Oncology, up from $178.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $844.4 million in Q1 2024 to a low of $178.9 million in Q4 2025.
• The 5-year median for Total Non-Current Liabilities is $580.7 million (2022), against an average of $561.2 million.
• Across the five-year window, Total Non-Current Liabilities jumped 41.01% in 2024 and tumbled 67.54% in 2025, its largest moves.
• Coherus Oncology's Total Non-Current Liabilities stood at $614.8 million in 2022, then jumped by 32.2% to $812.7 million in 2023, then sank by 32.18% to $551.2 million in 2024, then sank by 67.54% to $178.9 million in 2025, then advanced by 3.92% to $185.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $185.9 million (Q1 2026), $178.9 million (Q4 2025), and $427.3 million (Q3 2025), per Business Quant data.